BioAtla to Present Groundbreaking Research at IASLC Conference
BioAtla, Inc. (Nasdaq: BCAB), a leading biotechnology company dedicated to developing advanced therapeutics for solid tumors, has announced an exciting opportunity to present its research at the upcoming International Association for the Study of Lung Cancer (IASLC) 2024 Hot Topic in Basic & Translational Science Meeting. This prestigious event is set to take place in Washington, DC, bringing together experts in the field.
Presentation Highlights
The focus of BioAtla's poster presentation will center on the characterization of the mutated KRAS genotype and its correlation with clinical outcomes in patients suffering from advanced non-small cell lung cancer (NSCLC). This research showcases the innovative therapeutic approach of Mecbotamab Vedotin, a groundbreaking CAB-AXL-ADC.
Key Details of the Presentation
The presentation will occur during a poster reception on December 14, at 5:40 PM ET. The specific details of the poster include:
- Title: Characterization of Mutated KRAS Genotype and Clinical Outcomes in Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, a CAB-AXL-ADC
- Authors: A diverse team including Julia Rotow, Grace K. Dy, and others.
- Poster Number: PP01.03
- Session Type: Poster Reception
About BioAtla, Inc.
BioAtla is a clinical-stage biotechnology firm with a significant focus on creating Condition Active Biologics (CABs) tailored to optimize the efficacy of monoclonal and bispecific antibodies while minimizing toxicity. This unique platform technology allows for a more precise targeting of cancer cells compared to traditional approaches.
Innovative Therapeutics in Development
At the forefront of BioAtla’s pipeline, several first-in-class CABs are undergoing clinical trials. Mecbotamab Vedotin is notable not only for its innovative mechanism but also for its potential to lead to better patient outcomes with reduced side effects. Additonally, another promising candidate, Ozuriftamab Vedotin, is also progressing through its clinical phases, both showing the company's commitment to pioneering methodologies in treating cancer.
Operational Footprint
Operating globally with a significant presence in San Diego, California, and a partnership in Beijing, China, BioAtla has established itself as a strong player in the biopharmaceutical landscape. The company’s bold approach to biotechnology through CAB technology enables efficient and predictable manufacturing, alongside a robust patent portfolio with over 780 active patents worldwide.
Contact Information
If you are interested in more information about BioAtla’s innovations or wish to learn more about their presentations, please contact Richard Waldron, CFO of BioAtla, at 858.356.8945 or via email at rwaldron@bioatla.com.
Frequently Asked Questions
1. What is BioAtla presenting at the IASLC meeting?
BioAtla will present research focused on the mutated KRAS genotype and its effects on NSCLC patients treated with Mecbotamab Vedotin.
2. When will the presentation take place?
The poster presentation is scheduled for December 14, 2024, from 5:40 PM to 6:40 PM ET.
3. Where can I find BioAtla’s presentation materials?
Presentation materials will be available on the company’s website after the presentation concludes.
4. Who are the authors involved in the research?
A team of experienced researchers, including Julia Rotow and Grace K. Dy, contributed to the study.
5. What are the main benefits of BioAtla’s CAB technology?
BioAtla’s CAB technology offers better efficacy, reduced toxicity, and cost-effective manufacturing, establishing a significant advantage in cancer treatment development.
